<tt id="6hsgl"><pre id="6hsgl"><pre id="6hsgl"></pre></pre></tt>
          <nav id="6hsgl"><th id="6hsgl"></th></nav>
          国产免费网站看v片元遮挡,一亚洲一区二区中文字幕,波多野结衣一区二区免费视频,天天色综网,久久综合给合久久狠狠狠,男人的天堂av一二三区,午夜福利看片在线观看,亚洲中文字幕在线无码一区二区
          您現(xiàn)在的位置: > Language Tips > Audio & Video > Special Speed News  
           





            Once-daily pill could simplify HIV treatment
          [ 2006-02-06 15:57 ]


          I’m Steve Ember with the VOA Special English Health Report.


          Myers Squibb and Gilead Sciences have combined many H.I.V. drugs into a single pill
          Sometimes the best medicine is more than one kind of medicine. Malaria, tuberculosis and H.I.V./AIDS, for example, are all treated with combinations of drugs.

          But that can mean a lot of pills to take. It would be simpler if drug companies combined all the medicines into a single pill, taken just once a day.

          Now, two companies say they have done that for people just starting treatment for H.I.V., the virus that causes AIDS. The companies are Bristol-Myers Squibb and Gilead Sciences.

          They have developed a single pill that combines three drugs currently on the market. Bristol-Myers Squibb sells one of them under the name Sustiva. Gilead combined the others, Emtriva and Viread, into a single pill in two thousand four.

          Combining drugs involves more than technical issues. It also involves issues of competition if the drugs are made by different companies. The new once-daily pill is the result of what is described as the first joint venture agreement of its kind in the treatment of H.I.V.

          In January the New England Journal of Medicine published a study of the new pill. Researchers compared its effectiveness to that of the widely used combination of Sustiva and Combivir. Combivir contains two drugs, AZT and 3TC. The researchers say that after one year of treatment, the new pill suppressed H.I.V. levels in more patients and with fewer side effects.

          Gilead paid for the study. Professor Joel Gallant at the Johns Hopkins School of Medicine in Baltimore, Maryland, led the research. He is a paid adviser to Gilead and Bristol-Meyers Squibb as well as the maker of Combivir, GlaxoSmithKline.

          GlaxoSmithKline reacted to the findings by saying that a single study is of limited value. It says the effectiveness of Combivir has been shown in each of more than fifty studies.

          The price of the new once-daily pill has not been announced. But Gilead and Bristol-Myers Squibb say they will provide it at reduced cost to developing countries.

          They plan in the next few months to ask the United States Food and Drug Administration to approve the new pill.

          There are limits to who could take it because of the different drugs it contains. For example, pregnant women are told not to take Sustiva because of the risk of birth disorders.

          Experts say more than forty million people around the world are living with H.I.V.

          This VOA Special English Health Report was written by Cynthia Kirk. Read and listen to our reports at voaspecialenglish.com. I’m Steve Ember.

          Vocabulary

           

           

           
           
           




          主站蜘蛛池模板: 日韩精品 在线一区二区| 韩国三级网一区二区三区| 无码人妻丝袜在线视频| 天天干天天射天天操| 国产在线无码不卡播放| 高h喷水荡肉爽文np肉色学男男| 国产av一区二区三区综合| 成人无码视频97免费| 久久久久久久久久国产精品| 五月婷婷久久中文字幕| 国产亚洲精品AA片在线爽| 国产一区二区三区导航| 吉川爱美一区二区三区视频| 亚洲av永久无码精品漫画| 精品日韩亚洲av无码| 国产欧美一区二区三区视频在线观看| 国产精品乱一区二区三区| 国产综合色产在线精品| 亚洲va精品中文字幕| 天天噜噜日日久久综合网| 亚洲免费人成在线视频观看| 综合亚洲伊人午夜网| 国产一区二区不卡91| 亚洲另类激情专区小说婷婷久| 少妇人妻综合久久中文| 熟女精品国产一区二区三区 | 少妇尿尿一区二区在线免费| 免费a级毛视频| 亚洲欧美另类精品久久久| 日本五十路熟女一区二区| 人妻少妇精品视频专区| 九九re线精品视频在线观看视频 | 亚洲日韩久热中文字幕| 高潮潮喷奶水飞溅视频无码| 亚洲伊人久久综合影院| 国产99视频精品免费观看9| 性奴sm虐辱暴力视频网站 | 高清国产欧美一v精品| 女同在线观看亚洲国产精品| 国产欧美日韩精品丝袜高跟鞋| 久久综合国产色美利坚|